
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc. has made significant strides in RNA editing technology, particularly with the unveiling of KRRO-121, a liver-targeted therapeutic that stabilizes glutamine synthetase (GS) and enhances ammonia clearance, addressing critical unmet medical needs in urea cycle disorders (UCD) and hepatic encephalopathy (HE) markets valued at approximately $1.5 billion and $2.0 billion, respectively. Robust preclinical data from animal models support KRRO-121’s efficacy in improving ammonia levels after challenges, which could lead to substantial pharmacoeconomic benefits by reducing hospitalizations and crises associated with these conditions. The company's strategic advancement towards an Investigational New Drug (IND) filing in the second half of 2026, accompanied by promising preclinical results demonstrating up to 40% editing efficiency, reinforces a positive outlook on its future growth and potential market impact.
Bears say
Korro Bio has experienced a negative stock performance, primarily due to disappointing results from its KRRO-110 program and the challenges associated with advancing its pipeline candidates, particularly KRRO-121, which introduces significant risks related to clinical trials. Additionally, the potential for unfavorable clinical outcomes and regulatory disagreements with the FDA and EMA heightens uncertainty around the company's future profitability and operational effectiveness. Furthermore, the threat of evolving competitive treatments and possible legal issues related to intellectual property could adversely impact Korro Bio's market position and financial stability.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares